Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Vitrafy Life Sciences Ltd. ( (AU:VFY) ) has shared an announcement.
Vitrafy Life Sciences Limited has successfully completed a phase 1 blood platelet study with the US Army Institute of Surgical Research and received a $4.8 million grant from the Australian Government to support its VCU2 development and commercialization plans. The company is progressing in its U.S. market expansion, having hired a key executive and maintaining a strong financial position with $34 million in cash and term deposits. In the aquaculture sector, Vitrafy has shown promising results with its cryopreserved salmon milt, comparable to fresh milt, and is planning further collaborations. In bovine applications, Vitrafy is preparing for an on-site trial with Select Sires Inc., which could lead to further engagement while retaining its intellectual property rights.
More about Vitrafy Life Sciences Ltd.
Vitrafy Life Sciences Limited is an Australian company specializing in cryopreservation solutions, focusing on the development and commercialization of technologies for the preservation of biological materials. The company is actively engaged in the animal health sector, particularly in aquaculture and bovine semen cryopreservation, and is expanding its market presence in the U.S.
YTD Price Performance: -14.12%
Average Trading Volume: 27,565
For detailed information about VFY stock, go to TipRanks’ Stock Analysis page.